{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Epratuzumab",
  "nciThesaurus": {
    "casRegistry": "205923-57-5",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).",
    "fdaUniiCode": "3062P60MH9",
    "identifier": "C1887",
    "preferredName": "Epratuzumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129822",
      "C20401"
    ],
    "synonyms": [
      "EPRATUZUMAB",
      "Epratuzumab",
      "Humanized Anti-CD22 Monoclonal Antibody IgG1",
      "LymphoCide",
      "epratuzumab",
      "hLL2"
    ]
  }
}